在严重阻塞性睡眠呼吸暂停中PAI-1的奇怪作用
Tea Friščić1, Edvard Galić1,2, Domagoj Vidović3
1Clinical Hospital Sveti Duh, 10000 Zagreb, Croatia.
Biomedicines
|June 27, 2024
概括
对阻塞性睡眠呼吸暂停 (OSA) 的持续正气道压力 (CPAP) 治疗没有显著改变 PAI-1 水平,但显示出改善纤维素分解的趋势. 治疗后D-二聚物增加和纤维素素减少.
科学领域:
- 心血管医学 心血管医学
- 睡眠医学 睡眠医学
- 血液学 血液学 血液学
背景情况:
- 血原激活剂抑制剂-1 (PAI-1) 与纤维素分解,动脉动脉生成,衰老和炎症有关.
- 阻塞性睡眠呼吸暂停 (OSA) 与升高的PAI-1和心血管疾病 (CVD) 有关.
研究的目的:
- 研究CPAP治疗对严重OSA患者凝血参数和PAI-1的影响.
主要方法:
- 对57名新诊断的严重OSA患者进行了前性,受控研究.
- 在37名具有良好的粘附性患者中,在CPAP治疗6个月之前和之后分析凝血参数和PAI-1.
主要成果:
- 在CPAP后观察到,D-二元的显著增加 (p=0.0282) 和纤维素原的显著减少 (p=0.0075).
- 在CPAP治疗之前和之后,没有发现PAI-1水平的显著差异 (p=0.9367).
结论:
- 在严重的OSA患者中,CPAP治疗表现出改善纤维解质能力的趋势.
- 虽然凝血标志物发生了变化,但PAI-1水平保持不变,这表明在OSA治疗中存在复杂的调节机制.
相关概念视频
Sleep Apnea
140
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
The condition is more prevalent among...
140
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
195
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
195
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Mechanical Ventilation III: Noninvasive Ventilation
97
Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
Noninvasive Positive-Pressure Ventilation...
97
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152


